Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Janux Therapeutics's JANX-007?
JANX-007 is a fusion protein commercialized by Janux Therapeutics, with a leading Phase I program in Metastatic Castration-Resistant Prostate Cancer...
JANX-007 by Janux Therapeutics for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
JANX-007 is under clinical development by Janux Therapeutics and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According...
Risk adjusted net present value: What is the current valuation of Janux Therapeutics's JANX-007?
JANX-007 is a fusion protein commercialized by Janux Therapeutics, with a leading Phase I program in Metastatic Castration-Resistant Prostate Cancer...